NICE in UK refuses to recommend crizotinib for ROS1+ NSCLC

Last week the National Institute for Health and Care Excellence (NICE) decided not to recommend Xalkori for the treatment of ROS-positive non-small cell lung cancer in the United Kingdom. More information here:

NICE Appraisal Consultation Document

NICE shoots down Pfizer’s Xalkori in ROS1-positive patients, inviting a CDF proposal instead (from Fierce Biotech)

One thought on “NICE in UK refuses to recommend crizotinib for ROS1+ NSCLC

Comments are closed.